GB0320638D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0320638D0
GB0320638D0 GBGB0320638.0A GB0320638A GB0320638D0 GB 0320638 D0 GB0320638 D0 GB 0320638D0 GB 0320638 A GB0320638 A GB 0320638A GB 0320638 D0 GB0320638 D0 GB 0320638D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0320638.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0320638.0A priority Critical patent/GB0320638D0/en
Publication of GB0320638D0 publication Critical patent/GB0320638D0/en
Priority to BRPI0414062A priority patent/BRPI0414062B8/pt
Priority to PCT/EP2004/009804 priority patent/WO2005021028A1/en
Priority to RU2006110533/15A priority patent/RU2389501C2/ru
Priority to US10/570,097 priority patent/US7968518B2/en
Priority to DE602004022061T priority patent/DE602004022061D1/de
Priority to SI200431200T priority patent/SI1663287T1/sl
Priority to AU2004268382A priority patent/AU2004268382A1/en
Priority to PT04764762T priority patent/PT1663287E/pt
Priority to DK04764762T priority patent/DK1663287T3/da
Priority to SG200809555-6A priority patent/SG149063A1/en
Priority to HK06112329.1A priority patent/HK1091732B/en
Priority to EP04764762A priority patent/EP1663287B1/en
Priority to MXPA06002394A priority patent/MXPA06002394A/es
Priority to ES04764762T priority patent/ES2328361T3/es
Priority to JP2006525712A priority patent/JP4688806B2/ja
Priority to HR20090535T priority patent/HRP20090535T1/hr
Priority to PL04764762T priority patent/PL1663287T3/pl
Priority to TW093126578A priority patent/TWI342782B/zh
Priority to NZ545495A priority patent/NZ545495A/en
Priority to KR1020067004342A priority patent/KR101116968B1/ko
Priority to CA2537137A priority patent/CA2537137C/en
Priority to EP06125649.1A priority patent/EP1797892B1/en
Priority to CNA2004800246044A priority patent/CN1842343A/zh
Priority to ZA200601550A priority patent/ZA200601550B/en
Priority to IL173909A priority patent/IL173909A/en
Priority to TNP2006000071A priority patent/TNSN06071A1/en
Priority to MA28865A priority patent/MA28032A1/fr
Priority to IS8371A priority patent/IS2917B/is
Priority to NO20061479A priority patent/NO20061479L/no
Priority to AU2008203031A priority patent/AU2008203031B2/en
Priority to CY20091100955T priority patent/CY1110506T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB0320638.0A 2003-09-03 2003-09-03 Organic compounds Ceased GB0320638D0 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
GBGB0320638.0A GB0320638D0 (en) 2003-09-03 2003-09-03 Organic compounds
CNA2004800246044A CN1842343A (zh) 2003-09-03 2004-09-02 经修饰环孢菌素用于治疗hcv疾病的用途
ES04764762T ES2328361T3 (es) 2003-09-03 2004-09-02 Uso de ciclosporinas modificadas para el tratamiento de trastornos por hcv.
JP2006525712A JP4688806B2 (ja) 2003-09-03 2004-09-02 Hcv障害の処置のための修飾シクロスポリンの使用
RU2006110533/15A RU2389501C2 (ru) 2003-09-03 2004-09-02 Применение модифицированных циклоспоринов для лечения заболеваний, вызванных hcv
US10/570,097 US7968518B2 (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of HCV disorders
DE602004022061T DE602004022061D1 (de) 2003-09-03 2004-09-02 Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
SI200431200T SI1663287T1 (sl) 2003-09-03 2004-09-02 Uporaba modificiranih ciklosporinov za zdravljenje HCV motenj
AU2004268382A AU2004268382A1 (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of HCV disorders
PT04764762T PT1663287E (pt) 2003-09-03 2004-09-02 Utilização de ciclosporinas modificadas para o tratamento de doenças por vhc
PL04764762T PL1663287T3 (pl) 2003-09-03 2004-09-02 Zastosowanie zmodyfikowanych cyklosporyn do leczenia schorzeń wywołanych przez HCV
SG200809555-6A SG149063A1 (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of hcv disorders
HK06112329.1A HK1091732B (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of hcv disorders
EP04764762A EP1663287B1 (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of hcv disorders
MXPA06002394A MXPA06002394A (es) 2003-09-03 2004-09-02 Uso de ciclosporinas modificadas para el tratamiento de trastornos de hcv.
BRPI0414062A BRPI0414062B8 (pt) 2003-09-03 2004-09-02 uso de ciclosporinas modificadas para o tratamento de distúrbios por hcv
HR20090535T HRP20090535T1 (hr) 2003-09-03 2004-09-02 Uporaba modificiranih ciklosporina za liječenje hcv poremećaja
TW093126578A TWI342782B (en) 2003-09-03 2004-09-02 Treatment of hcv disorders
DK04764762T DK1663287T3 (da) 2003-09-03 2004-09-02 Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
PCT/EP2004/009804 WO2005021028A1 (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of hcv disorders
NZ545495A NZ545495A (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of Hepatitis C and HCV disorders
KR1020067004342A KR101116968B1 (ko) 2003-09-03 2004-09-02 Hcv 질환의 치료를 위한 개질된 시클로스포린의 용도
CA2537137A CA2537137C (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of hcv disorders
EP06125649.1A EP1797892B1 (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of HCV disorders
ZA200601550A ZA200601550B (en) 2003-09-03 2006-02-22 Use of modified cyclosporins for the treatment of HCV disorders
IL173909A IL173909A (en) 2003-09-03 2006-02-23 Use of modified cyclosporins in the preparation of pharmaceutical compositions for the treatment of hcv disorders
TNP2006000071A TNSN06071A1 (en) 2003-09-03 2006-03-02 Use of modified cyclosporins for the treatment of hcv disorders
MA28865A MA28032A1 (fr) 2003-09-03 2006-03-10 Utilisation de cyclosporines modifiees pour le traitement de troubles lies au vhc
IS8371A IS2917B (is) 2003-09-03 2006-03-24 Notkun breyttra sýklósporína til að meðhöndla HCV kvilla
NO20061479A NO20061479L (no) 2003-09-03 2006-03-31 Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser
AU2008203031A AU2008203031B2 (en) 2003-09-03 2008-07-09 Use of modified cyclosporins for the treatment of HCV disorders
CY20091100955T CY1110506T1 (el) 2003-09-03 2009-09-16 Χρηση των τροποποιημενων κυκλοσπορινων για τη θεραπεια των διαταραχων hcv

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0320638.0A GB0320638D0 (en) 2003-09-03 2003-09-03 Organic compounds

Publications (1)

Publication Number Publication Date
GB0320638D0 true GB0320638D0 (en) 2003-10-01

Family

ID=28686843

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0320638.0A Ceased GB0320638D0 (en) 2003-09-03 2003-09-03 Organic compounds

Country Status (29)

Country Link
US (1) US7968518B2 (cg-RX-API-DMAC10.html)
EP (2) EP1797892B1 (cg-RX-API-DMAC10.html)
JP (1) JP4688806B2 (cg-RX-API-DMAC10.html)
KR (1) KR101116968B1 (cg-RX-API-DMAC10.html)
CN (1) CN1842343A (cg-RX-API-DMAC10.html)
AU (2) AU2004268382A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0414062B8 (cg-RX-API-DMAC10.html)
CA (1) CA2537137C (cg-RX-API-DMAC10.html)
CY (1) CY1110506T1 (cg-RX-API-DMAC10.html)
DE (1) DE602004022061D1 (cg-RX-API-DMAC10.html)
DK (1) DK1663287T3 (cg-RX-API-DMAC10.html)
ES (1) ES2328361T3 (cg-RX-API-DMAC10.html)
GB (1) GB0320638D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20090535T1 (cg-RX-API-DMAC10.html)
IL (1) IL173909A (cg-RX-API-DMAC10.html)
IS (1) IS2917B (cg-RX-API-DMAC10.html)
MA (1) MA28032A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA06002394A (cg-RX-API-DMAC10.html)
NO (1) NO20061479L (cg-RX-API-DMAC10.html)
NZ (1) NZ545495A (cg-RX-API-DMAC10.html)
PL (1) PL1663287T3 (cg-RX-API-DMAC10.html)
PT (1) PT1663287E (cg-RX-API-DMAC10.html)
RU (1) RU2389501C2 (cg-RX-API-DMAC10.html)
SG (1) SG149063A1 (cg-RX-API-DMAC10.html)
SI (1) SI1663287T1 (cg-RX-API-DMAC10.html)
TN (1) TNSN06071A1 (cg-RX-API-DMAC10.html)
TW (1) TWI342782B (cg-RX-API-DMAC10.html)
WO (1) WO2005021028A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200601550B (cg-RX-API-DMAC10.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1091975E (pt) 1998-07-01 2006-05-31 Debiopharm Sa Nova ciclosporina com um perfil de actividade melhorado
CA2518265A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
BRPI0513370A (pt) 2004-07-14 2008-05-06 Novartis Ag uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
ATE490778T1 (de) * 2004-10-01 2010-12-15 Debiopharm Sa Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
PT1802650E (pt) * 2004-10-01 2011-12-30 Scynexis Inc Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
ES2314731T3 (es) 2004-11-22 2009-03-16 Astellas Pharma Inc. Analogo de ciclosporina.
WO2006071619A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
NZ555142A (en) * 2004-12-23 2010-03-26 Novartis Ag Compounds for flaviviridae treatment
RU2427372C2 (ru) 2005-06-17 2011-08-27 Новартис Аг Применение санглиферина для лечения вируса гепатита с
WO2007041632A2 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
CN101316606B (zh) * 2005-09-30 2015-05-27 西尼克斯公司 治疗和预防丙型肝炎感染的方法和药物组合物
WO2007041631A1 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
KR101273681B1 (ko) 2005-10-26 2013-06-25 아스텔라스세이야쿠 가부시키가이샤 신규 시클릭 펩티드 화합물
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
CA2652662C (en) 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
KR101089112B1 (ko) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. 활성 전자 관리
KR20090083902A (ko) * 2006-10-12 2009-08-04 노파르티스 아게 개질된 사이클로스포린의 용도
WO2008069917A2 (en) * 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
CN101616683A (zh) 2007-01-04 2009-12-30 德比奥法姆股份有限公司 用于治疗Ullrich先天性肌营养不良的非免疫抑制性环孢霉素
EP2150269B1 (en) * 2007-05-02 2012-11-21 Astellas Pharma Inc. New cyclic peptide compounds
EP2193807A4 (en) * 2007-08-24 2012-09-12 Univ Sapporo Medical CYCLOSPORIN A-BINDING PROTEIN
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
JP5820722B2 (ja) * 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びhcv感染の治療におけるその使用
MX2011001152A (es) * 2008-07-30 2011-06-09 Isotechnika Pharma Inc Moleculas de analogo de ciclosporina no-inmunesupresoras.
MX2011003259A (es) * 2008-09-24 2011-04-21 Astellas Pharma Inc Compuesto de peptido y metodo para producir el mismo.
CN102202679B (zh) 2008-11-06 2014-05-07 帝柏奥研究制药有限公司 环十一缩酚酸肽化合物及其作为药物的用途
US8536114B2 (en) * 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
RU2492181C2 (ru) * 2009-01-30 2013-09-10 Энанта Фармасьютикалс, Инк. Аналоги циклоспорина для предупреждения или лечения инфекции гепатита с
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
CN102869367A (zh) 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2012045704A1 (en) 2010-10-05 2012-04-12 Novartis Ag New treatments of hepatitis c virus infection
RU2013129824A (ru) 2010-11-30 2015-01-10 Новартис Аг Новое лечение инфекции вируса гепатита с
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
AU2011342284C1 (en) 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
KR20140007927A (ko) 2011-03-31 2014-01-20 노파르티스 아게 C형 간염 바이러스 감염을 치료하기 위한 알리스포리비르
WO2012131061A1 (en) 2011-04-01 2012-10-04 Novartis Ag Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases
RU2013150344A (ru) 2011-04-13 2015-05-20 Новартис Аг Лечение инфекции вируса гепатита алисповиром
US20140228281A1 (en) 2011-09-27 2014-08-14 Novartis Ag Alisporivr for treatment of hepatitis c virus infection
WO2013169616A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmacokinetic modulation with alisporivir
WO2013181339A2 (en) 2012-06-01 2013-12-05 Allergan, Inc. Cyclosporin a analogs
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
HK1223843A1 (zh) 2013-08-26 2017-08-11 Enanta Pharmaceuticals, Inc. 用於預防或治療丙型肝炎的環孢菌素類似物
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Mebmt側鏈已環化之環孢菌素衍生物
US20230330132A1 (en) * 2020-08-24 2023-10-19 Nanomerics Limited Viral inhibitors
WO2026119137A1 (en) * 2024-12-03 2026-06-11 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclosporin analogues and uses in hepatitis b therapies

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質,その製造法および中間体
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
FI111730B (fi) * 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 C型肝炎の予防・治療剤
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
ES2240868T3 (es) 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
PT1091975E (pt) 1998-07-01 2006-05-31 Debiopharm Sa Nova ciclosporina com um perfil de actividade melhorado
CZ200350A3 (cs) 2000-07-13 2003-05-14 Sankyo Company Limited Aminoalkoholové deriváty
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
CA2426381A1 (en) * 2000-10-19 2002-04-25 Fujisawa Pharmaceutical Co., Ltd. Cell damage inhibitor
JP2002125683A (ja) * 2000-10-27 2002-05-08 Tokyoto Igaku Kenkyu Kiko インターフェロンの有効性を予測する方法並びにそれに用いられるプライマー及びプローブ
MXPA03008755A (es) 2001-03-26 2004-02-18 Novartis Ag Derivados de 2-amino-propanol.
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
KR100913269B1 (ko) 2001-09-27 2009-08-21 교린 세이야꾸 가부시키 가이샤 디아릴 황화물 유도체, 그의 염 및 이를 이용한 면역억제제
JP4152884B2 (ja) 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
US20030213603A1 (en) 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘
GB0313444D0 (en) 2003-06-11 2003-07-16 Midland Medical Technologies L Modular dysplasia cup
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
ATE490778T1 (de) 2004-10-01 2010-12-15 Debiopharm Sa Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
WO2006071619A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment

Also Published As

Publication number Publication date
PT1663287E (pt) 2009-09-03
NO20061479L (no) 2006-06-02
KR20060132798A (ko) 2006-12-22
DE602004022061D1 (de) 2009-08-27
CA2537137A1 (en) 2005-03-10
NZ545495A (en) 2010-01-29
TW200524626A (en) 2005-08-01
JP2007504260A (ja) 2007-03-01
EP1797892B1 (en) 2013-10-23
US20070275884A1 (en) 2007-11-29
RU2006110533A (ru) 2007-10-10
MA28032A1 (fr) 2006-07-03
CY1110506T1 (el) 2015-04-29
RU2389501C2 (ru) 2010-05-20
AU2004268382A1 (en) 2005-03-10
EP1663287A1 (en) 2006-06-07
AU2008203031A1 (en) 2008-07-31
BRPI0414062B8 (pt) 2021-05-25
IL173909A0 (en) 2006-07-05
SI1663287T1 (sl) 2009-10-31
ZA200601550B (en) 2007-05-30
WO2005021028A1 (en) 2005-03-10
EP1797892A1 (en) 2007-06-20
CA2537137C (en) 2013-05-28
MXPA06002394A (es) 2006-06-20
EP1663287B1 (en) 2009-07-15
JP4688806B2 (ja) 2011-05-25
US7968518B2 (en) 2011-06-28
AU2008203031B2 (en) 2011-04-07
SG149063A1 (en) 2009-01-29
CN1842343A (zh) 2006-10-04
DK1663287T3 (da) 2009-11-09
HRP20090535T1 (hr) 2009-11-30
HK1091732A1 (en) 2007-01-26
IS8371A (is) 2006-03-24
PL1663287T3 (pl) 2009-12-31
KR101116968B1 (ko) 2012-03-14
IL173909A (en) 2011-03-31
ES2328361T3 (es) 2009-11-12
TNSN06071A1 (en) 2007-10-03
BRPI0414062B1 (pt) 2019-06-25
IS2917B (is) 2014-12-15
TWI342782B (en) 2011-06-01
BRPI0414062A (pt) 2006-10-24

Similar Documents

Publication Publication Date Title
TWI347941B (en) Organic compounds
IL175435A0 (en) Organic compounds
GB0402677D0 (en) Organic compounds
GB0301259D0 (en) Organic compounds
GB0303503D0 (en) Organic compounds
GB0326601D0 (en) Organic compounds
GB0325603D0 (en) Organic compounds
GB0307553D0 (en) Organic compounds
GB0302876D0 (en) Organic compounds
GB0326602D0 (en) Organic compounds
GB0300095D0 (en) Organic compounds
GB0302748D0 (en) Organic compounds
GB0301471D0 (en) Organic compounds
GB0301938D0 (en) Organic compounds
GB0303506D0 (en) Organic compounds
GB0312086D0 (en) Organic compounds
GB0311971D0 (en) Organic compounds
GB0302991D0 (en) Organic compounds
GB0306071D0 (en) Organic compounds
GB0324543D0 (en) Organic compounds
GB0320311D0 (en) Organic compounds
GB0301470D0 (en) Organic compounds
GB0300590D0 (en) Organic compounds
GB0301561D0 (en) Organic compounds
GB0325172D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)